Septic Shock - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Septic Shock - Pipeline Review, H2 2016

Septic Shock - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Septic Shock - Pipeline Review, H2 2016
Published Sep 28, 2016
92 pages — Published Sep 28, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Septic Shock - Pipeline Review, H2 2016, provides an overview of the Septic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Septic Shock
- The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects
- The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Septic Shock

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Septic Shock
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing

  
Source:
Document ID
GMDHC8496IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Septic Shock Overview91
Therapeutics Development102
  Pipeline Products for Septic Shock Overview101
  Pipeline Products for Septic Shock Comparative Analysis111
Septic Shock Therapeutics under Development by Companies122
Septic Shock Therapeutics under Investigation by Universities/Institutes141
Septic Shock Pipeline Products Glance154
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
  Unknown Stage Products181
Septic Shock Products under Development by Companies191
Septic Shock Products under Investigation by Universities/Institutes201
Septic Shock Companies Involved in Therapeutics Development2116
  Adrenomed AG211
  Ferring International Center S.A.221
  Huons Co., Ltd.231
  InflaRx GmbH241
  Inotrem S.A.251
  Lixte Biotechnology Holdings, Inc.261
  Noxxon Pharma AG271
  Octapharma AG281
  Orion Oyj291
  Peptinov SAS301
  Pharmazz, Inc.311
  Spider Biotech321
  Takeda Pharmaceutical Company Limited331
  Therashock, LLC341
  ViiV Healthcare Limited351
  XImmune AB361
Septic Shock Therapeutics Assessment379
  Assessment by Monotherapy Products371
  Assessment by Target382
  Assessment by Mechanism of Action402
  Assessment by Route of Administration422
  Assessment by Molecule Type442
Drug Profiles4637
  3K3A-APC Drug Profile462
  adrecizumab Drug Profile481
  AM-12 Drug Profile491
  Aspidasept Drug Profile501
  BC-1215 Drug Profile511
  BMS-936559 Drug Profile522
  BTZO-2 Drug Profile541
  Drug for Sepsis and Septic Shock Drug Profile551
  HBN-1 Drug Profile561
  HBN-3 Drug Profile571
  HBN-4 Drug Profile581
  HU-003 Drug Profile591
  IFX-1 Drug Profile602
  L-257 Drug Profile621
  LB-100 Drug Profile632
  levosimendan Drug Profile654
  M-6229 Drug Profile691
  Motrem Drug Profile701
  NOXD-21 Drug Profile711
  PMZ-2010 Drug Profile721
  pooled plasma (human) Drug Profile731
  Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock Drug Profile741
  R-190 Drug Profile752
  SB-056 Drug Profile771
  selepressin Drug Profile781
  Small Molecule to Inhibit TNF-Alpha for Septic Shock Drug Profile791
  SP-14 Drug Profile801
  SP-9 Drug Profile811
  Synthetic Peptides for Inflammation and Infectious Disorders Drug Profile821
Septic Shock Dormant Projects832
Septic Shock Discontinued Products851
Septic Shock Product Development Milestones865
  Featured News &Press Releases861
    Sep 13, 2016: Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem, a TREM-1 Pathway Modulator for the Treatment of Septic Shock861
    Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery861
    Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody871
    Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan881
    Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients891
    Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock901
Appendix912
  Methodology911
  Coverage911
  Secondary Research911
  Primary Research911
  Expert Panel Validation911
  Contact Us911
  Disclaimer921

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Septic Shock - Pipeline Review, H2 2016" Sep 28, 2016. Alacra Store. May 07, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Septic-Shock-Pipeline-Review-H2-2016-2088-16609>
  
APA:
Global Markets Direct - Market Research. (2016). Septic Shock - Pipeline Review, H2 2016 Sep 28, 2016. New York, NY: Alacra Store. Retrieved May 07, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Septic-Shock-Pipeline-Review-H2-2016-2088-16609>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.